Analytical Data
-
Gene name
PAX9
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55771
-
Expression Region
Met1~Leu341
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAX9, a member of the paired box (PAX) gene family, plays a crucial role in various developmental processes, particularly in tooth and craniofacial development. Its involvement in signaling pathways during the early stages of embryogenesis has made it a focal point in studies related to congenital anomalies, such as tooth agenesis, cleft palate, and other craniofacial malformations. The study of PAX9 recombinant protein is essential for understanding its functional mechanisms and the molecular interactions it mediates. Researchers have been focusing on producing PAX9 recombinant proteins to explore their structure and activity, which can provide insights into its role in genetic disorders and developmental biology. Additionally, investigating the binding characteristics of PAX9 with other transcription factors can aid in identifying potential therapeutic targets for conditions arising from its dysfunction. The ongoing research aims to elucidate the importance of post-translational modifications and protein conformational changes in its activity and interaction with DNA, further contributing to the comprehension of craniofacial and dental abnormalities. Understanding PAX9’s biological functions through recombinant protein studies could ultimately lead to advancements in regenerative medicine and gene therapy, offering new avenues for treating patients affected by PAX9-related conditions. This research not only enhances our understanding of developmental biology but also holds potential implications for clinical applications in genetics and developmental medicine.
